TR-987 Emerging Drug Insight

“TR-987 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about TR-987 for chronic wounds in the seven major markets. A detailed picture of the TR-987 for chronic wounds in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the TR-987 for chronic wounds. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TR-987 market forecast analysis for chronic wounds in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic wounds.

Drug Summary

TR-987, a drug candidate, activates immune cells developed to defend against pathogenic microorganisms. Using the principle of biologic pattern recognition, the TR-987 gel utilizes a purified insoluble biological polysaccharide (β-glucan) “skeleton” of a yeast cell that is used as a decoy to attract macrophages to the wound site.

Tissue Repair is in the final stages of closing its Phase II program. It completed Phase IIB clinical trial and end-of-study statistical analysis in 2020 for its chronic wound product, TR-987. It plans to commence pivotal Phase III trials for its chronic wound product in 2022, subject to FDA approval.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TR-987 description, mechanism of action, dosage and administration, research and development activities in chronic wounds.
• Elaborated details on TR-987 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TR-987 research and development activities in chronic wounds across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TR-987.
• The report contains forecasted sales of for chronic wounds till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic wounds.
• The report also features the SWOT analysis with analyst views for TR-987 in chronic wounds.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TR-987 Analytical Perspective by DelveInsight

In-depth TR-987 Market Assessment

This report provides a detailed market assessment of TR-987 for chronic wounds in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

TR-987 Clinical Assessment

The report provides the clinical trials information of TR-987 for chronic wounds covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic wounds is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TR-987 dominance.
• Other emerging products for chronic wounds are expected to give tough market competition to TR-987 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TR-987 in chronic wounds.
• Our in-depth analysis of the forecasted sales data of TR-987 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TR-987 in chronic wounds.

Key Questions

• What is the product type, route of administration and mechanism of action of TR-987?
• What is the clinical trial status of the study related to TR-987 in chronic wounds and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TR-987 development?
• What are the key designations that have been granted to TR-987 for chronic wounds?
• What is the forecasted market scenario of TR-987 for chronic wounds?
• What are the forecasted sales of TR-987 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to TR-987 for chronic wounds?
• Which are the late-stage emerging therapies under development for the treatment of chronic wounds?